Independent Policy Research

Independent Policy Research on
Heartworm Prevention Access
and Prescribing Standards

This site presents independent, data-driven research on heartworm prevention access, clinical proportionality, and evidence-based prescribing standards. Our analysis examines the evidence base for current annual testing practices, the cost barriers they create for dog owners in high-prevalence regions, and the gap between FDA-approved label requirements and standard practice protocols. The goal is to inform evidence-based policy discussions among veterinary professionals, researchers, and public health advocates.

8
Major ML preventives reviewed; none require renewal testing on FDA label
~2,000
Tests needed to find one positive in a consistently-dosed compliant dog in a moderate-prevalence county
Derived from CAPC county-level positivity data applying the compliance-gap correction from Atkins et al. (2014). Full methodology detailed in peer-reviewed publications and white paper.
2005
Year the requirement originated, as an FDA surveillance request rather than a clinical standard
$268K
Estimated cost to detect one positive in a compliant dog in a moderate-prevalence county (CAPC data + Atkins 2014)

The Issue

The evidence behind current testing practices

At most U.S. veterinary clinics today, a dog owner who wants to refill their pet's heartworm prevention medication, even after years of documented continuous use, must first pay for an annual antigen test and wellness visit before the prescription will be renewed. No exceptions. No waivers.

"The heartworm test is not a state-mandated legal requirement, but it is a strict veterinary requirement required to prescribe prevention. Technically, a doctor can [prescribe without it]."

Tampa Bay area veterinary clinic staff member, March 2026

This research does not argue against heartworm testing. It examines the evidence base for mandatory annual testing as a precondition for renewing prevention prescriptions for established, compliant dogs, and asks whether the clinical data, cost implications, and guideline development process support that standard as currently applied.

The annual testing requirement has been operationalized into standard clinic policy, particularly following the 2024 AHS guideline update. This research does not question the motivations behind those policies. It examines whether the evidence supports the mechanism, and whether the access barrier the requirement creates has ever been weighed against the benefits it claims.

The American Heartworm Society, the primary source of this standard, lists among its sponsors the manufacturers of both the ML preventive drugs the guidelines govern and IDEXX Laboratories, the manufacturer of the diagnostic test the guidelines recommend annually. The owners most likely to face the annual testing cost as a genuine barrier are concentrated in the region with the highest heartworm prevalence, the lower Mississippi River Valley, where infection rates are highest and household incomes are lowest. A requirement intended to catch heartworm infections may leave more infections undetected than it identifies. Questions about guideline development transparency and the disclosure of sponsor relationships are examined in the full white paper.

FDA Label Review

A direct review of all 8 major FDA-approved ML preventive labels confirms: not one requires pre-administration testing at prescription renewal. All testing language is limited to initiation. Advantage Multi contains no testing language at all.

Primary Source Confirmation

The annual testing recommendation traces to a 2005 FDA request to gather data on preventive efficacy in the field. Not a patient safety finding. Not a clinical trial. A surveillance request. AHS Research Chair Tom Nelson DVM confirmed in March 2026 that the annual testing recommendation was introduced at the FDA's request for post-market surveillance data, not as a patient safety determination. The geographic limitation was silently removed when AHS translated it into a national standard.

THE AHS PROVIDED WAIVER

For years before the current de facto requirement emerged, signed informed-consent waivers coexisted with AHS recommendations as standard practice. The AHS still publishes an official Heartworm Preventive Waiver template (© 2020) on its website today. The shift to waiver refusal is a recent institutional policy, not a discovery that waivers were always impermissible.

The Financial Alignment

Manufacturer satisfaction guarantees (up to $1,500 coverage) explicitly condition eligibility on annual negative testing. Owners who sign a waiver are waiving a financial warranty, not bypassing a clinical safeguard. This distinction is not disclosed at the point of care.

The Access Problem

Published research (Wang et al., 2014, 9 million tests) identifies income as a statistically significant predictor of heartworm prevalence. The states with the highest heartworm rates are also the poorest. No manufacturer, guideline body, or government program funds subsidized testing access in those areas. The requirement's cost falls hardest precisely where heartworm risk is greatest.

The Ethics of a Prerequisite

Does the requirement meet the standard medicine applies to every other access restriction?

Human medicine has spent decades developing frameworks for when a screening requirement that restricts access to care is ethically justified. Two are foundational: the Wilson-Jungner criteria for screening programs and the Beauchamp-Childress principles of biomedical ethics. Both turn on proportionality: a restriction on autonomy is justified only when its benefits clearly outweigh its burdens. Applied to a uniform annual-testing prerequisite, three principles are directly implicated.

Autonomy · The decisive principle

An informed owner who understands the disease risk in their area and has decided how to care for their animal cannot obtain prevention without submitting to the test. There is no mechanism to honor an informed refusal. The prerequisite does not inform a decision; it removes one, taking the decision from the person the law and the veterinary relationship both recognize as its holder. No empirical finding is required to see the difficulty: a requirement that overrides informed consent is hard to reconcile with a principle the rest of medicine treats as fundamental.

Justice

A flat requirement falls hardest on those least able to absorb it. The most common income bracket among dog-owning households sits near the threshold below which discretionary costs force real tradeoffs, and a large share of pet owners report they could not cover an unexpected veterinary bill of a few hundred dollars without taking on debt. A fixed cost imposed before prevention can be accessed is not felt equally. It is a minor formality for some owners and a genuine barrier for others, and it lands most heavily in exactly the lower-income, higher-prevalence regions where keeping dogs on prevention matters most.

Proportionality

The most basic question, whether this requirement does more good than harm, has never been studied. No published data establish what share of owners would decline the test if offered the choice, how large the population of consistently compliant dogs is for whom an annual test adds little, or what the requirement costs owners forced to weigh it against other needs. A rule that overrides autonomy and imposes an uneven burden cannot be called proportionate when its net effect on animal welfare has never been measured.

None of this argues against testing or prevention. Both matter. It asks whether making the test a categorical precondition, rather than a recommendation an informed owner can accept or decline, meets the ethical standard medicine applies to every other access restriction.

Research & Projects

Active research program

Original data collection, policy analysis, and peer-reviewed submissions examining prevention access, cost barriers, and clinical proportionality.

Original Data

Multi-State Clinic Practice Survey

Systematic audit of heartworm prevention prescribing policies across veterinary practices in FL, MS, TX, CA, and MN. Documents waiver acceptance rates, precondition language, and ownership structure.

Early results (n=63):

82.5% of practices required annual testing regardless of compliance history. Corporate-owned practices required it at 90%; independently owned at 76%, suggesting administrative policy standardization as a driver independent of clinical judgment.

Methodology note: These figures are drawn from a preliminary practice inquiry and do not meet the methodological requirements for peer-reviewed research. Results are presented as indicative background data only and are not cited in peer-reviewed submissions. This survey has been discontinued.

Policy White Paper

Annual Heartworm Antigen Testing Prior to Preventive Renewal: A Review of Clinical Evidence, Guideline Development, and Owner Decision-Making

50-page analysis integrating clinical, autonomy-based, and structural lines of argument across six sections:

  • → Compliance-adjusted NNS analysis across representative U.S. counties
  • → FDA DailyMed label review of all 8 major ML preventives
  • → Primary source confirmation from AHS Research Chair on guideline origins
  • → AHS guideline language evolution 2005 → 2014 → 2024
  • → Manufacturer guarantee structure and COI disclosure analysis
  • → Mediterranean natural experiment: Canary Islands OTC model and outcomes
  • → Socioeconomic access analysis using Wang et al. 9-million-test dataset
Download PDF →

Proposed Study

LMRV Regional Access Study with Income Overlay

Proposed analysis linking CAPC county-level prevalence data with household income distributions and prevention access barriers across the Lower Mississippi River Valley, the region with the highest heartworm burden and lowest median household income in the U.S.

Seeking veterinary academic collaborators and co-investigators

The Evidence

Three independent lines of analysis.
The same conclusion.

The clinical argument examines test reliability, residual infection risk, and proportionality. The autonomy argument examines prescribing authority and informed consent frameworks. The structural argument examines guideline origins, sponsor relationships, and the absence of transparency disclosures. Together they raise questions a professional standard of this scope should be able to answer.

🔬

The Clinical Case

The safety rationale fails at renewal for consistently-dosed, asymptomatic patients.

  • The renewal paradox: if slow-kill was underway, it was authorized by the prior prescription, so the renewal test detects it retroactively rather than preventively
  • ML-induced antigen suppression delays detectability to ~9 months, so the test is least reliable in exactly the scenario it targets
  • Reach-back efficacy achieves ~95% worm burden reduction in compliant dogs, and the biological event resolved months before month 12
  • CAPC data: positivity rates are consistently lowest in dogs with documented continuous prevention
  • The proportion of dogs in the tested population that are genuinely established compliant patients has never been measured, meaning the denominator required to calculate actual infection risk in this subpopulation does not exist in any published literature. The requirement's proportionality has not been formally evaluated for the population it most directly affects
  • The SNAP test and entire IDEXX confirmatory cascade cannot identify ML-resistant strains, so the resistance-detection rationale cannot be fulfilled by the test being mandated
  • Adulticide (melarsomine) works against resistant and susceptible adult worms, so a positive result doesn't change the treatment protocol
  • A documented multi-year purchase and dispensing record is a meaningful compliance signal: even among dogs flagged for suspected preventive failure, the purchase record correctly identifies compliance gaps in more than 80% of cases (Atkins et al., 2014). The requirement implicitly treats this signal as worthless, an assumption with no published empirical justification
⚖️

The Autonomy Case

Veterinary prescribing authority was delegated to protect the individual patient, not to enforce population surveillance or manufacturer warranty terms.

  • Waiver-based prescribing coexisted with AHS recommendations as standard practice for years before the current de facto requirement emerged; the shift to waiver refusal is a recent institutional policy requiring its own justification
  • AHS guidelines are advisory, not statutory; no U.S. state practice act directly incorporates them as binding law
  • Under 2024 AHS guidelines, waivers are no longer offered at most practices, despite the AHS maintaining an official Waiver template
  • Manufacturer warranty eligibility requires annual testing, so owners signing waivers are waiving a financial guarantee, not a clinical safeguard
  • The rabies analogy fails: unlike statutory vaccine mandates, heartworm resistance tracking is an industry initiative without legislative standing
  • The AHS publishes an official Heartworm Preventive Waiver template, yet its 2024 guidelines say prescribing without testing is "NOT RECOMMENDED," a contradiction the AHS has not resolved
🔗

The Structural Case

The guideline origin is post-market surveillance, not individual patient safety, and the body that sets the standard lists among its primary sponsors the manufacturers of the products the standard governs.

  • AHS Platinum sponsors: Boehringer Ingelheim, Elanco, Zoetis, all major ML manufacturers
  • AHS Silver sponsors: IDEXX Laboratories (mandated test manufacturer) and Merck Animal Health
  • Testing requirement originated as an FDA surveillance request (confirmed: Tom Nelson DVM, March 2026)
  • AHS guideline language hardened progressively: 2005 recommendation → 2014 stronger language → 2024 explicit "NOT RECOMMENDED," with no corresponding change in heartworm biology
  • IDEXX: Silver AHS sponsor, mandated test manufacturer, and vendor of the entire confirmatory cascade that a positive result triggers
  • No equivalent mandatory pre-prescription testing exists in any EU heartworm-endemic country, including Mediterranean nations with year-round transmission
  • Canary Islands (Spain): canine heartworm prevalence fell from 67% (1994) to 15.8% (2020) under OTC-access model without mandatory testing (Montoya-Alonso et al., 2024)
  • Documented European resistance concentrations have not emerged under the OTC-access framework over the same period in which the U.S. developed its confirmed resistance hotspot
📋

Primary Source

AHS Research Chair and past president Tom Nelson DVM confirmed in direct correspondence (March 2026): "The AHS first began to recommend annual testing in the 2005 Guidelines... at the request of the FDA" based on a paper focused on post-market efficacy surveillance, not individual patient safety. The geographic limitation the FDA applied was not carried forward into the national standard.

Research Gap

The policy shift eliminated a tool that was never measured

No published research quantifies what proportion of dog owners elected signed waivers when the option was offered, or what clinical outcomes followed. No AHS, CAPC, or independent study has examined waiver election rates before or after the 2014 or 2024 guideline changes. No outcome data compares heartworm prevalence or clinical results between waiver-accepting and non-waiver practices.

The Numbers

What the testing requirement actually costs

Calculate what annual heartworm prevention costs for your dog, and what the testing requirement adds on top of it.

Annual Cost Calculator

Select your dog's size, preferred medication, and local pricing. See what the testing requirement adds above the cost of protection alone.

$65$150

Range $65–$150; national average per AVMA 2025. Actual price varies by region and practice type.

$35$75

Cited range $35–$75 (Sulik K. DVM, PetMD 2025). Default: confirmed real-world price including draw and materials.

Prevention Only
Heartgard Plus, 26–50 lbs (annual)
$151
Cost of protection: the medication itself
Prevention + Required Testing Visit
Prevention + antigen test + wellness exam
$421
$151 prevention + $56 test + $214 exam
Testing Requirement Cost
Annual test + exam cost attributable to the testing precondition
$270
+179% above prevention cost alone
Note: some owners would incur an annual wellness exam regardless of the testing requirement. The marginal cost attributable solely to the testing precondition is, at minimum, the antigen test fee.
Prevention
$151
With Requirement
$421

If an owner skips prevention due to this cost barrier and their dog contracts heartworm, treatment costs $600–$3,000+: melarsomine injections, doxycycline, chest X-rays, 6–8 weeks crate rest. Severe caval syndrome cases: $3,000–$6,000.
Source: Sulik K. DVM, reviewed by Coates J. DVM, PetMD April 2025

Sources: Prevention prices: Chewy.com, 6-month supply × 2, March 2026 (standard retail). Antigen test: Sulik K. DVM, PetMD Apr. 2025 ($35–$75 range). Wellness exam: AVMA 2025 data via Pawlicy Advisor Dec. 2025. Treatment: PetMD Apr. 2025. This calculator is illustrative; individual prices vary by region and practice.

Research & Resources

Peer-Reviewed Publications,
White Paper, and Resources

This research is published in peer-reviewed veterinary literature and presented in detailed policy analysis. Press inquiries welcome.

Personal copies: If you'd like a personal copy of any published works or letters, refer to the contact section below for where to send your request.

📰

JAVMA Viewpoint

Is Annual Dirofilaria immitis Antigen Testing at Preventive Renewal Proportionate to the Residual Infection Risk in Documented-Compliant Dogs?

Uses Number Needed to Screen analysis to demonstrate that uniform annual testing requirements lack proportionality when compliance-adjusted infection risk varies dramatically by geography and prevalence.

→ Read on JAVMA (DOI: 10.2460/javma.26.04.0312)
📰

JAVMA Viewpoint

Are Common Clinical Protocols Prioritizing Detection Over Prevention in Canine Dirofilaria immitis?

Demonstrates that compliance monitoring and adherence interventions, rather than annual testing, should be the primary approach to preventing heartworm infections in established patients on prevention.

→ Read on JAVMA (DOI: 10.2460/javma.26.04.0293)
💬

Professional Exchange

Official response from Dr. Nelson and the American Heartworm Society, with formal author response

Published in JAVMA. Direct professional correspondence examining key points raised in the initial Viewpoints, with evidence-based replies from the research team.

DOIs available in JAVMA or via the contact form below.

📄

Policy White Paper

Annual Heartworm Antigen Testing Prior to Preventive Renewal: A Review of Clinical Evidence, Guideline Development, and Owner Decision-Making

Comprehensive policy analysis with three integrated lines of argument (clinical, autonomy-based, and structural), supported by FDA label analysis, primary source correspondence, AHS guideline review, manufacturer documentation, and CAPC prevalence data.

↓ Download White Paper (PDF)

Press Contact

For interview requests, background information, or to request primary source documentation:

[email protected]

HeartwormChoice.org
Tampa Bay, Florida

Sourcing

This analysis draws on FDA label data, AHS guideline and waiver documentation, primary-source correspondence, and peer-reviewed prevalence research. Full citations appear in the white paper and published Viewpoints.